	US 11,964,004 B2
	Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
Xinli Henry Lin, Shenzhen (CN)
Assigned to SHENZHEN BAY LABORATORY, Shenzhen (CN)
Filed by SHENZHEN BAY LABORATORY, Shenzhen (CN)
Filed on Mar. 30, 2022, as Appl. No. 17/709,403.
Claims priority of provisional application 63/169,196, filed on Mar. 31, 2021.
Prior Publication US 2022/0387564 A1, Dec. 8, 2022
Int. Cl. A61K 38/48 (2006.01); A61P 7/02 (2006.01)

CPC A61K 38/484 (2013.01) [A61P 7/02 (2018.01)]

7 Claims

1. A short in vivo half-life and in vivo unstable recombinant microplasmin obtained by alanine scanning mutagenesis, wherein the recombinant microplasmin is obtained by expressing in a bacteria host, or refolding and purifying when the recombinant microplasmin is expressed as an insoluble inclusion body, the in vivo half-life of the recombinant microplasmin is about 2.75 to about 28.5 minutes;

wherein the short in vivo half-life and in vivo unstable recombinant microplasmin includes at least one of wild-type, Gly739Ala, Arg582Ala, Met585Ala, Lys607Ala, Phe587Ala, Ser608Ala, Arg610Ala, Glu641Ala, Pro642Ala.